Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.

Autor: Pietruck F; Department of Nephrology and Hypertension, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany. frank.pietruck@uni-essen.de, Kiel G, Birkel M, Stahlheber-Dilg B, Philipp T
Jazyk: angličtina
Zdroj: Biopharmaceutics & drug disposition [Biopharm Drug Dispos] 2005 May; Vol. 26 (4), pp. 135-41.
DOI: 10.1002/bdd.440
Abstrakt: Background: Candesartan cilexetil is a possible treatment for hypertension in renal allograft recipients. Tacrolimus is widely used as an immunosuppressant following renal transplantation. The aim of this study was to evaluate the effect of multiple doses of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus.
Methods: Twelve patients received oral doses of tacrolimus twice daily for 12 days from study day -2 until day 10, single oral doses of candesartan cilexetil placebo on study days -2 to -1, single oral doses of 2 mg candesartan cilexetil once daily on study days 1 to 3, oral doses of 4 mg candesartan cilexetil once daily on study days 4 to 6, and oral doses of 16 mg candesartan cilexetil once daily on study days 7 to 9. Serial blood samples were collected on days -1, 6 and 9 and were analysed for tacrolimus using microparticle enzyme immunoassay.
Results: Mean C(max,ss) and AUC(tau,ss) values for tacrolimus on day 6 (4 mg candesartan) and day 9 (16 mg candesartan cilexetil) were similar to those on day -1 (tacrolimus alone). Renal function did not change under treatment with candesartan cilexetil compared with baseline. The co-administration of multiple oral doses of cardesartan cilexetil with oral doses of tacrolimus was well tolerated.
Conclusions: Concomitant administration of multiple doses of candesartan cilexetil does not alter the steady-state pharmacokinetics of tacrolimus.
(Copyright (c) 2005 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: